Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AZD8205 + AZD9574 + AZD2936
- Development stage
- Phase 2
- Lead developer
- AstraZeneca
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
AZD8205 + AZD9574 + AZD2936 is a triplet combination therapy being developed by AstraZeneca for the treatment of advanced or metastatic solid tumors, including breast, ovarian, endometrial, and biliary tract cancers. The regimen consists of three distinct agents: AZD8205 (puxitatug samrotecan), an antibody-drug conjugate (ADC) targeting B7-H4 with a topoisomerase I inhibitor payload; AZD9574, a brain-penetrant, selective PARP1 inhibitor that induces synthetic lethality in DNA repair-deficient cells; and AZD2936 (rilvegostomig), a bispecific antibody targeting the immune checkpoints PD-1 and TIGIT. This combination is designed to synergistically target tumor cells through direct cytotoxicity, inhibition of DNA damage response, and reactivation of the anti-tumor immune response. It is currently being evaluated in Sub-Study 4 of the Phase I/IIa BLUESTAR master protocol trial (NCT05123482).
- Other names
- puxitatug samrotecan + AZD9574 + rilvegostomig
02
Targets
VTCN1 (V-set domain containing T cell activation inhibitor 1)PARP1 (Poly (adp-ribose) polymerase 1)PDCD1 (Programmed cell death protein 1 receptor)TIGIT (T cell immunoreceptor with Ig and ITIM domains)
Beyond the preview
Go deeper on AZD8205 + AZD9574 + AZD2936.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AZD8205 + AZD9574 + AZD2936.